A miniature osmotic pump has been developed (Osmet) with ALZA, Palo Alto, USA, which can be swaliowed, will pass through the stomach and small intestine and then deliver its contents (240 il) over eight hours in the large bowel. In vitro studies showed the pumps started to discharge after four to five hours and emptied at a reasonably constant rate of 20*4 ,ul/h from 9-16 h (9.6%/h). In vivo studies using gamma-scintigraphy in seven healthy subjects show that the pumps left the fasting stomach at 1*2 h (range 0-3) and arrived in the caecum by 6*4 h (range 5-9). Mean start-up time was 5-3 (0.2) h and the rate of discharge was 15*9 4l/h for pumps studied from 6-12 h and 17*2 ,li/h for those studied from 10-20 h. This device is simple, safe and effective for the delivery of tracer substances to the caecum and colon without interfering with patients' normal lifestyle.
Delivering tracer substances, drugs or other materials directly into the lumen of the caecum and colon in man, whether for research or therapeutic purposes, poses considerable problems. Most substances given by mouth are absorbed from the small intestine and whilst some may be re-excreted in bile as conjugated forms oral dosing does not provide a reliable way of getting substantial amounts of many active compounds into the large bowel. Various enteric coatings have been devised to slow down the release in the small bowel. These often rely on changes in pH in the gut to determine onset of drug delivery. Unfortunately, there is no pH in the colon which is not encountered higher up in the gut' 2 SO it is difficult to use this for reliable colonic dosing.
In the study of colonic metabolism a variety of techniques have been tried including intestinal intubation,34 breath hydrogen and methane measurements,56 rectal dialysis,7'8 extensive studies of faeces,9 10 ileostomy content,"I examination of necropsy material2 and in vitro work '2 13 but these techniques either greatly disturb normal physiology or are so limited in scope that the overall role in digestive physiology and metabolism of the large bowel remains either unquantitated or unknown.
A system has therefore been developed which allows delivery of small quantities of known substances into the caecum using a miniature osmotic pump designed to pass through the stomach and small intestine before discharging its contents over an eight to 12 h period in the caecum and colon.
Methods
OSMET PUMP (Fig 1) This is a cylindrical device 25 mm x 7 mm made from a styrene-butadiene copolymer and having a capacity of about 200 ji. An enteric coating designed to be insoluble in gastric juice but soluble at pH 7 covers the outside of the pump and the osmotic force is provided by a salt layer within the semipermeable copolymer exterior. The pump is filled with a syringe and blunt 25 gauge needle through the opening at one end, 14 (from Pancrex V powder 10 g/l), polyethylene glycol (PEG) 4000 5 g/l, and 12 ml/l of a solution containing a mixture of antibiotics (nalidixic acid 360 mg/I, vancomycin 48 mg/l, chloramphenicol 240 mg/l, neomycin 216 mg/l, penicillin 120 mg/l).
The studies were carried out in 50 ml conical flasks containing 20 ml fluid at 37°C and were shaken in an orbital incubator at 1000 rpm. All flasks were sampled at zero and 24 h and from four flasks samples were taken at hourly intervals from one to 14 h and from the other four flasks from 10-23 h.
Duplicate 100 ptl samples of fluid from each flask were taken directly into glass liquid scintillation vials, 10 ml BDH Cocktail EX 'Scintron' added, the vial shaken then placed in a Philips scintillation counter PW 4540 at 4°C and left for two to three hours before being counted for two minutes. Standards of the original '4C-PEG were run and disintegrations per minute (dpm) calculated using external standardisation. Account was taken of the progressive decrease in volume of the solution in the conical flasks in calculating efflux of '4C-PEG from the pumps.
IN VIVO STUDIES
Seven healthy men aged 29-45 years took part in these studies. Pumps were filled with a solution containing 1 MBq "'In-DTPA. In the first part of the study four subjects swallowed a pump on two occasions at 08 00 h after a 12 h fast. Together with the pump a 20 ml drink containing 3 MBq 99mTc in water was given. The location of the pump in the gut and the amount of activity remaining within it was measured using gamma-scintigraphy hourly from 0-12 h and then at 24 h. In the second part of the study three subjects swallowed a pump on a total of four occasions at 10 pm (not fasting) and gammascintigraphy was performed hourly from 10-14 h then two hourly from 16-22 h. During the study all subjects ate a controlled diet. In the first part there were two diets, either low fibre containing 9-0 kJ, 80 g protein, 64 g fat (P:S ratio 0 14), 330 g carbohydrate, and 13-5 g dietary fibre; or a high fibre diet containing 9-1 kJ, 80 g protein, 64 g fat (P:S ratio 0 29), 339 g carbohydrate, and 53 g fibre. ' 6 Each of the four subjects were studied once whilst eating each diet. In the second part of the study all subjects ate the high fibre diet throughout. The subjects ate and drank normally during the study and pumps were recovered by faecal collection and residual activity measured in a gamma-counter.
GAMMA-SCINTIGRAPHY
Subjects were scanned whilst lying down using dual radionucleide imaging for 300 secs anteriorly and posteriorly, with an IGE maxicamera 400 AT. Data were recorded on a Nodecroft V77 computer and stored before analysis. For "'In a region of interest (ROI) was defined around the image of the pump on the visual display unit and the amount of activity in this area expressed as a fraction of total activity in the whole field of view. A geometric mean of anterior and posterior fractions was taken.'7 The location of the pump was determined by inspection of the 99mTc picture, which outlined the gut, with the "'In-DTPA ROI superimposed.
The estimated effective dose equivalent to the whole body per administration was calculated to be 0 37 mSv for "'In-DTPA and 0 05 mSv for 99mTc assuming an intestinal transit time of 48 h. The dose to the gut was 4-8 mSv for "'In-DTPA and 0 7 mSv for 99mTc.
The study was approved by the Ethical Committee of the Dunn Nutrition Unit on 18 November 1986 and the use of isotopes by the Administration of Radioactive Substances Advisory Committee (ARSAC) of the Department of Health and Social Security, Certificate No RPC-83-16/2.
Results

IN VITRO STUDIES
Average fill volume for the eight pumps was 241 p1 (range 218-262). The four pumps monitored from 0-14 h started to deliver between four and five hours (an additional eight pumps used in preliminary studies also started to deliver at this time). Figure 2 shows that delivery rate gradually increased to a maximum over five hours and then from nine to 16 h was approximately constant at 20-4 1tl/h during which time 67% of the dose was delivered. Pumps were emptied by 19-20 h and total recovery of the counts of 14C-PEG at 24 h was 102-6% (2X2% SEM). The proportion of the total dose from each pump emptying per hour was constant and is shown in Figure 3 . From six to 17 h the pumps emptied at 8-2% per hour.
IN VIVO STUDIES
The pumps were swallowed without difficulty and led to no untoward effects. The position of the pumps in the gut was followed by gammascintigraphy with 99mTc outlining the anatomy of the gut and the exact location of the pump definable by the "'In-DTPA image. Figure 4 shows a selection of scans from a single subject. In Figure 4a the 99mTc lies almost entirely in the stomach (at 10 min) but the pump can be seen to move immediately into the duodenum. By one hour (4b) most of the small bowel is outlined by 99mTc with the pump somewhere in the ioo.*---. middle. At seven hours (4c) the 99mTc outlines the right colon with the pump visible in the caecum and still as a discrete circle indicating no significant discharge of contents. Subsequent films (4d-4f) show the pump traversing the colon with the bowel outlined by both 99mTc and "'In-DTPA discharged from it. The onset of discharge from the pump was characterized by asymmetry in the shape of the I'In-DTPA image or the appearance of a trail of "'In-DTPA from the pump (Fig 4d) and by a reduction in the fraction of activity remaining in the region of interest. On average pumps had left the stomach by 1 2 h (Table) and arrived in the caecum by 6 Figure 5 . The rate of delivery was similar for pumps 24 Time (h) Figure 5 : % "'In-DTPA remaining in Osmet minipump in vivo. *=eight pumps swallowed at 8 am after an overnight fast and studied by gamma-scintigraphy in four subjects from 0-12 h. O=four pumps in three subjects swallowed at 10 pm and then studiedfrom 10-24 h. studied from 0-12 h (7 i5%/h, n=8) and 10-22 h (6-6%/h, n=4) but the overnight pumps appeared to start up later and at equivalent times contained about 16% more than the pumps given at breakfast time.
On recovery the pumps contained 1.0 (0-6)% of the original dose of "'In-DTPA (n= 11; one pump lost down the toilet).
Discussion
The problem of defining events, particularly in the caecum, has been approached in a variety of ways. These techniques either disturb the normal physiological pattern -for example, intubation, use of ileostomy patients, in vitro studies, or are relatively indirect and imprecise (breath hydrogen/methane studies, rectal dialysis, examination offaeces). The advent of devices such as the Osmet mini-osmotic pump presents a unique opportunity for studies of colonic function.
The Osmet pump is one ofa number ofdevices which have been developed over the past 10 years primarily with the objective of improving drug delivery by controlling the rate of drug release in the body and by better targeting.'8 Examples of these systems presently in use include transdermally administered nitroglycerin, oestradiol, scopolamine and clonidine; orally administered (OROS) phenylpropanolamine (appetite suppressant) and calcium ascorbate. Other devices are available for intra-uterine and ocular use.
Products being developed include orally administered albuterol/salbutamol for asthma, nefedipine for angina, prazosin for blood pressure and also periodontal systems.
The Osmet pump'9 is a cylindrical container with a rigid outer casing composed of a styrene/ butadiene copolymer which allows water to pass through into a salt layer made up of sodium chloride and polyethylene glycol. The centre of the pump is a collapsible reservoir of flexible impermeable material which can be filled with a wide range of substances soluble in water, ethanol (5%), PEG or as a suspension. These systems are so designed that the duration of delivery of most solutions can be varied from a few hours to days. The enteric coating is pH sensitive and designed to resist breakdown in the stomach, but then to dissolve gradually in the small intestine. The time taken to break down the enteric coating plus that to start-up delivery by the pump is three to four hours, sufficient for it to reach the ileocaecal region in fasting subjects.
We undertook to compare the in vitro and in vivo performance of the pumps in order to establish their behaviour in man and also, given good comparability of the two systems, to allow future validation to be done mainly in vitro as the costs of in vivo validation using gammascintigraphy are substantial.
In vitro validation is relatively straightforward although our initial attempts to do this with simulated colonic fluid and 'IC glycine and '4C acetate were unsuccessful because of microbial degradation of these substances during the 24 h period at 37°C. We therefore chose to use a low concentration of relatively non-degradable '4C-PEG in addition to a cocktail of antibiotics in the test system. Overall recovery of '4C-PEG was close to 100%. An initial hour at pH 2 was chosen to simulate the time spent in the fasting stomach and pancreatic enzymes were added to the simulated colonic fluid since they are present in high concentrations in the large bowel202' as well as small bowel. In these conditions the pumps behaved uniformly well with a start up time of four to five hours.
The pumps were given to subjects fasting because in previous studies of the transit of different dosage forms through the gut by Davis et a122 pumps given with breakfast stayed in the stomach for 10-12 h. Whilst the coating on the present pumps might have prevented discharge of the contents during this time, it is preferable to aim to get the pumps to the colon as quickly as possible. Fasting subjects in the present study were allowed to eat normally as soon as the pumps had left the pyloroduodenal area. Pumps given at night to non-fasted subjects seemed to be delayed in their transit through the stomach and small bowel as only two out of four were at the caecum at 10 h. This delay in transit might be related to sleep as well as to giving the pumps with food.
By six to seven hours, the time by which the pumps were definitely in the caecum, a maximum of 10% of the dose had been delivered. The majority of the dose should therefore be released in the colon over the next 10-12 h. Although small, the fraction of the total dose delivered in the ileum needs to be taken into account in designing tracer studies. Substances released in the ileum will be absorbed and thus escape degradation by caecal flora. If the end-products of metabolism of material released by the pump are different by bacterial and absorbed routes then these may be distinguished in blood, urine etc. But if they are similar then the site of absorption will not be definable.
The amount of time the capsule spends in different regions of the gut may be determined, using either contrast media or "'In-DTPA, and may aid in quantifying potential small bowel delivery and the location of large bowel delivery also. From examination of the gamma-scan pictures it can be predicted that the greater part of the dose would be delivered proximal to the hepatic flexure. Of the eight pumps studied from 0-12 h, seven were still in the right colon or at the hepatic flexure at 12 h, whilst one (Fig 4) 
